Overview

BRCA1 and BRCA2 are tumor suppressor genes, associated with inherited forms of breast and ovarian cancers. Mutations in both these genes are strongly implicated in hereditary breast, ovarian, and prostate cancers. Women carrying harmful BRCA1 variants face a 60 - 80% lifetime risk of breast cancer, while BRCA2 carriers face a 45–69% risk. Early and precise detection of these mutations is essential not only for confirming diagnosis but also for identifying at-risk individuals, guiding preventive strategies, family counseling, and targeted therapies.

The BRCA-Q Real-Time PCR Kit from Genes2Me is an advanced in vitro diagnostic solution for the qualitative detection of BRCA1 and BRCA2 mutations in clinical samples, including blood and FFPE tissues. With comprehensive mutation coverage, the BRCA-Q kit is designed to detect six high-risk mutations: five in the BRCA1 gene (185delAG, 300G [C61G], 2080delA, 4153delA, 5382insC) and one in the BRCA2 gene (6174delT). Independent primer-probe sets ensure mutation-specific amplification, while fluorescently labeled probes (FAM for BRCA targets, Cy5 for internal control) enable precise and parallel detection in a single workflow.

Built on highly sensitive real-time PCR technology, this kit empowers laboratories with accurate, fast, and reproducible results, enabling clinicians to make timely and informed decisions in cancer risk assessment, diagnosis, and treatment planning.